EG-MCV4

Meningococcal conjugate vaccine · EyeGene Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EG-MCV4, covering 2025-12-01 to 2025-12-01. Get the full timeline:

Most recent: Clinical Trial Update: Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old [Phase 2, Phase 3]

See pricing